NCT04739501

Trans-arterial Chemoembolization in Patients With Hepatocellular Carcinoma: A Study of Different Outcomes and Their Predictive Factors

Trans-arterial Chemoembolization in Patients With Hepatocellular Carcinoma

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 100 (estimated)
• Sponsor: Assiut University · Academic / Other
• Sex: All
• Age: 40 Years
• Healthy volunteers: Not accepted

Summary

Radiological response after trans arterial chemoembolization (TACE) is classified according to Modified Response Evaluation Criteria in Solid Tumors (mRECIST) to: complete response (CR) (disappearance of arterial enhancement), partial response (PR) ( at least a 30% decrease in the sum of diameters of viable enhancement), progressive disease (PD) (an increase of at least 20% in the sum of the diameters of viable enhancement, or appearance of new lesions), and stable disease (any cases that do not qualify for either partial response or progressive disease

Detailed description

POST-TACE response of treatment for cases of hepatocellular cancer

Conditions

• Liver Cancer

Interventions

Type	Name	Description
PROCEDURE	TACE	Trans-arterial chemoembolization in patients with hepatocellular carcinoma

Timeline

• Start date: 2020-12-01
• Primary completion: 2021-12-30
• Completion: 2022-03-30
• First posted: 2021-02-04
• Last updated: 2021-02-04

Locations

1 site across 1 country: Egypt